Adamas Pharmaceuticals (ADMS) PT Raised to $33 at JMP Securities Following GOCOVRI Approval and Strong Product Label
Tweet Send to a Friend
JMP Securities raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $33.00 (from $29.00) while maintaining a Market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
